BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Numerex Innovates Remote Monitoring of MicroMed Cardiovascular's Heart Pump Technology


5/18/2012 7:27:19 AM

ATLANTA, May 17, 2012 /PRNewswire/ -- Numerex Corp (NASDAQ: NMRX), a leading single source provider of secure machine-to-machine (M2M) products and services, announced today the company has developed a complete Device-Network-Application (DNA) solution for remote cellular monitoring of MicroMed Cardiovascular Inc.'s HeartAssist5® System.

Numerex led the innovation and development of the new wireless monitoring connectivity and software application for the HeartAssist5® System, the latter consisting of two devices developed by MicroMed: the HeartAssist5® Left Ventricular Assist Device (LVAD) and the MicroMed Controller. The MicroMed HeartAssist5® LVAD was originally developed by the world famous heart surgeon Dr. Michael DeBakey in partnership with NASA. It is the only LVAD with a precise, direct flow measurement system and cellular-based remote monitoring.

"The partnership with Numerex has been spectacular. They provided the expertise we need along with their Numerex DNA® solution to move our idea quickly and reliably to market," said Bryan Lynch, Vice President of product development at MicroMed.

Prior to Numerex implementing the new M2M technology, clinicians accessed device data after the body-worn external controller unit was physically plugged into the MicroMed Heart Attendant and transmitted via a local internet connection. This limited mobility and continuous reporting could not occur.

The MicroMed Cardiovascular team sought a solution to improve real-time visibility to the devices and engaged Numerex to integrate a cellular radio into the MicroMed Controller, provide cellular network services, and deliver a web-based application to consolidate and present the reported data for clinicians to review.

"This is a good example of the value-added services Numerex brings to their enterprise customers to deliver new solutions," said Mike Marett, Chief Revenue Officer of Numerex. "MicroMed brought their deep domain expertise and a strong core product to us. After which we applied our M2M expertise and leveraged our platforms to enable a rapid product evolution and ultimately enable the many new benefits associated with continuous connectivity and monitoring."

The MicroMed Cardiovascular M2M application was built using the secure, reliable Numerex FAST® platform. As part of the Numerex DNA® solution, the firmware was optimized to reduce the size of the data packet transmissions, ultimately optimizing from over 50MB to less than 4MB per month and resulting in significant efficiencies and cost savings. Remote monitoring of the device is now continuous and consistent, allowing for relevant device statistics to be reported around the clock. More importantly, any anomalies in the device are reported in real-time.

About MicroMed Cardiovascular Inc.

MicroMed is a pioneer in the field of Mechanical Circulatory Support. MicroMed makes a powerful, miniature, implantable electric LVAD or Left Ventricular Assist Device (the HeartAssist5®) that increases the cardiac output of a failing heart. The HeartAssist5® system is currently sold commercially outside of the United States and the wireless system is not yet approved for human use.

About Numerex

Numerex Corp (NASDAQ: NMRX) is a leading provider of machine-to-machine (M2M) business services, technology, and products used in the development and support of M2M solutions for the enterprise and government markets worldwide. The Company offers Numerex DNA® that includes hardware and smart Devices, cellular and satellite Network services, and software Applications that are delivered through Numerex FAST® (Foundation Application Software Technology). Customers typically subscribe to device management, network, and application services through hosted platforms. Business services enable the development of efficient, reliable, and secure solutions while simplifying and speeding up deployment through streamlined processes and comprehensive integration services. Numerex is ISO 27001 information security-certified. "Machines Trust Us®" represents the Company's focus on M2M data security, service reliability, and round-the-clock support of its customers' M2M solutions. For additional information, please visit www.numerex.com.

© 2012 Numerex Corp. All rights reserved. Numerex, the Numerex logo and all other marks contained herein are trademarks of Numerex Corp. and/or Numerex- affiliated companies. All other marks contained herein are the property of their respective owners.

This press release contains, and other statements may contain, forward-looking statements with respect to Numerex future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding growth trends and activities in the wireless data business. Forward-looking statements are typically identified by words or phrases such as "believe," "expect," "anticipate," "intend," "estimate," "assume," "strategy," "plan," "outlook," "outcome," "continue," "remain," "trend," and variations of such words and similar expressions, or future or conditional verbs such as "will," "would," "should," "could," "may," or similar expressions. Numerex cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. These forward-looking statements speak only as of the date of this press release, and Numerex assumes no duty to update forward-looking statements. Actual results could differ materially from those anticipated in these forward-looking statements and future results could differ materially from historical performance.

Numerex MediaContact:
Carrie Crabill
404 214-0722 ext 102

Investor Relations Contact:
Seth Potter
646 277-1230

SOURCE Numerex Corp



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES